- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2022-002679-12 | Sponsor Protocol Number: EOCRC1-22 | Start Date: 2023-06-01 | ||||||||||||||||||||||||||
Sponsor Name: Enterome SA | ||||||||||||||||||||||||||||
Full Title: A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of c... | ||||||||||||||||||||||||||||
Medical condition: Patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy . | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003792-41 | Sponsor Protocol Number: DAROTAXEL | Start Date: 2023-05-26 | ||||||
Sponsor Name: Erasmus MC | ||||||||
Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer. | ||||||||
Medical condition: metastatic castration-resistant prostate cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002312-23 | Sponsor Protocol Number: LY06006/MRCT-301 | Start Date: 2023-05-25 | |||||||||||
Sponsor Name: Shandong Boan Biotechnology Co., Ltd. | |||||||||||||
Full Title: A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmeno... | |||||||||||||
Medical condition: Postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BG (Ongoing) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003475-42 | Sponsor Protocol Number: GTAEXS617-001 | Start Date: 2023-05-23 | ||||||||||||||||||||||||||||||||||||
Sponsor Name: Exscientia AI Ltd | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors. | ||||||||||||||||||||||||||||||||||||||
Medical condition: advanced solid tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002407-37 | Sponsor Protocol Number: BET-PSMA-121 | Start Date: 2023-05-22 | |||||||||||
Sponsor Name: Blue Earth Therapeutics Limited | |||||||||||||
Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met... | |||||||||||||
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003398-51 | Sponsor Protocol Number: R-Pola-Glo | Start Date: 2023-05-16 | |||||||||||
Sponsor Name: Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||
Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in... | |||||||||||||
Medical condition: aggressive large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001781-35 | Sponsor Protocol Number: UKER-BC007-01 | Start Date: 2023-05-16 | |||||||||||
Sponsor Name: Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients... | |||||||||||||
Medical condition: Post-COVID syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000135-76 | Sponsor Protocol Number: ACE-01-22 | Start Date: 2023-05-15 | |||||||||||||||||||||
Sponsor Name: Adamed Pharma S.A. | |||||||||||||||||||||||
Full Title: Therapeutic Equivalence Study of Twice Daily Acetylsalicylic Acid Tablets 50 mg Compared to Once Daily Acetylsalicylic Acid Tablets 100 mg in Adult Patients Coronary Artery Disease (CAD) or Symptom... | |||||||||||||||||||||||
Medical condition: Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) or after Acute Coronary Syndrome (ACS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002818-13 | Sponsor Protocol Number: DEALSZ-2021-001 | Start Date: 2023-05-12 | |||||||||||
Sponsor Name: Charité-Universitätsmedizin Berlin | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit... | |||||||||||||
Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006456-14 | Sponsor Protocol Number: K321301 | Start Date: 2023-05-10 | |||||||||||
Sponsor Name: Kowa Research Institute, Inc. | |||||||||||||
Full Title: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety ... | |||||||||||||
Medical condition: In Fuchs endothelial corneal dystrophy (FECD), there is an increased rate of loss of endothelial cells, starting in the centre of Descemet’s membrane and spreading to the periphery, resulting in ex... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) DK (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |